Ted Schroeder
ceo nabriva therapeutics@ Cidara Therapeutics
View Ted Schroeder's Email
View Ted Schroeder's Email & Phone
Real-Time AI Research
0 search queries left
FlashIntel GPT
Hello! I'm FlashIntel GPT, your personal AI search assistant. Feel free to ask me anything about Ted Schroeder, and I'll do my best to assist you.
You

Tell me more about Ted Schroeder?

FlashIntel GPT

Ted Schroeder is a highly experienced professional with 38.8 years of work experience in the pharmaceutical industry. He has been the CEO of Nabriva Therapeutics plc, a leading pharmaceutical company, since its acquisition in 2020. Ted has also held various leadership positions in renowned companies such as Biocom California, Collegium Pharmaceutical, and Otonomy, Inc. He has a strong background in the biotechnology research field and has successfully developed new antibiotics for various diseases. Ted's expertise and leadership have contributed to the success of Zavante Therapeutics, a leading pharmaceutical company.
For inquiries about Phone Number and Email, please click here Unlock Contact

Research Details
Skills & Insights
Colleagues

Emails and Phone Numbers

@biocom.org
@cadencepharm.com
@collegiumpharma.com
+1 858442****
+1 615414****
View Emails and Phone Numbers
10 free lookups per month

About

With the acquisition of Zavante Therapeutics by Nabriva Therapeutics we have created the most differentiated company within the antibiotic space with two novel MOA antibiotics. Lefamulin tradename Xenleta IV/PO is the first pleuromutilin antibiotic for human use approved in The U.S., Europe and Canada for CABP. IV fosfomycin or CONTEPO, represents a new class of IV antibiotic in the US for cUTI. IV fosfomycin has been available in the EU and other parts of the world for more than 45 years and with the application of modern PK/PD principles has the potential to treat today's most relevant infections. Due to the differentiated MOA of both products they do not share any mechanisms of resistance with currently available antibiotics and thereby have limited potential to increase resistant pressure on existing classes of antibiotics. Additionally, In July 2020 we entered into a collaboration agreement with Merck to market and distribute their novel antibiotic for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Sivextro (tedizolid) in the U.S. Please see nabriva.com for further information on our company and our products.

...See More

Work Experience

6310 Nancy Ridge Drive, San Diego, CA, 92121, US

Biotechnology Research

80
Show More

Ted Schroeder's Professional Milestones

  • Chair Emeritus (2017-02-01~2018-02-01): Conducted groundbreaking research and achieved significant breakthroughs in the field.
  • Chair Of The Board Of Directors (2015-02-01~2017-02-01): Transformed the organization through strategic planning, aligning organizational principles and fostering strong partnerships.
Show More

Education

Rutgers University
Rutgers University

Mba,

Bs